Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus

查看全文 作　　者：Salahuddin [1]Mahmud;Jahida [2]Gulshan;MdBelayet [3]Hossain;Madhabi [1]Baidya;Rafia [4]Rashid;Farhana [5]Tasneem;Ahmed Rashidul [1]Hasan;Tanzila [1]Farhana;Mohammed Reaz [6]Mobarak;MdJahangir [7]Alam;Syed Shafi [1]Ahmed 机构地区：[1]Department of Pediatric Gastroenterology,Hepatology&Nutrition,Bangladesh Shishu Hospital&Institute,Dhaka,Bangladesh;[2]Institute of Statistical Research and Training(ISRT),University of Dhaka,Dhaka,Bangladesh;[3]Department of Pediatric Hematology&Oncology,Bangladesh Shishu Hospital&Institute,Dhaka,Bangladesh;[4]Department of Pediatric Gastroenterology,Dr.M R Khan Shishu Hospital&Institute of Child Health,Dhaka,Bangladesh;[5]Department of Pediatrics,BIHS General Hospital,Diabetic Association of Bangladesh,Dhaka,Bangladesh;[6]Department of Epidemiology&Research,Bangladesh Shishu Hospital&Institute,Dhaka,Bangladesh;[7]Bangladesh Shishu Hospital&Institute,Dhaka,Bangladesh 出　　处：《iLIVER》索引2023年第2卷第3期,共5页 基　　金：Ethical clearance was obtained from the ethical review committee of Bangladesh Shishu Hospital&Institute(No.Admin/1041/DSH/2021). 摘　　要：Background and aims:Currently,treatment with oral direct-acting antivirals is recommended for all hepatitis C virus(HCV)-infected pediatric patients.The aim of this study was to evaluate the efficacy and safety of sofosbuvir and ribavirin combination ther apy for children and adolescents in Bangladesh who are living with chronic HCV in fection.Methods:An experimental study was performed from January 2021 to December 2022.HCV polymerase chain reaction(PCR)-positive thalassemic children,who were 6–18 years of age,were enrolled by consecutive non-probability sampling.Clinical features were recorded,and investigations were performed.All patients were initially treated with sofosbuvir(200 mg for 6-to 11-year-olds and 400 mg for 12-to 18-year-olds)and ribavirin(10–15 mg/kg/day)and were assessed clinically on a four-weekly basis,along with liver-function testing.The total duration of therapy was 24 weeks.HCV PCR was done at the end of treatment and 12 weeks after the completion of treatment to see the sustained virological response.Results:There were 26 cases in total,with a mean age of 9.26?2.82 years;14 were males(53.8%),and 12 females(46.2%).Twenty-five(96.15%)patients achieved a sustained virological response,and the end-of-treatment PCR was negative.One patient(3.85%)was a nonresponder even after 24 weeks of treatment.The medication was well received,with only four patients(15.3%)reporting headaches that were reported untreated.Conclusion:The combination of sofosbuvir and ribavirin is effective in treating chronic HCV infection and is not accompanied by any major negative side effects. 关 键 词：Hepatitis C virus Direct-acting antivirals Sofosbuvir RIBAVIRIN